|
|
|
|
|
Board of Directors
Argos’ seven directors possess extensive experience in science and
medicine, industry, and venture capital, providing strategic direction
to the Company.
|
Hubert Birner, Ph.D., M.B.A. |
TVM Capital |
Chairman of the Board |
Jeffrey D. Abbey, M.B.A., J.D. |
Argos Therapeutics |
Director |
David W. Gryska |
Seattle Genetics |
Director |
Jean Lamarre |
Lamarre Consultants |
Director |
Philip R. (Phil) Tracy, J.D. |
Intersouth Partners |
Director |
Brian J. Underdown,
B.Sc., Ph.D. |
Lumira Capital |
Director |
Sander van Deventer, M.D., Ph.D. |
Forbion Capital |
Director |
|
Hubert Birner, Ph.D. M.B.A.
Chairman
Dr. Birner joined TVM Capital in 2000, and is a General Partner for life sciences in the firm’s Munich office. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and is a member of the Board of Directors of Evotec AG (Hamburg, Germany), BioXell SA (Milan, Italy), Spepharm Holding BV (Amsterdam, Netherlands), Proteon Therapeutics, Inc (Kansas City, Missouri), Transmolecular Inc.(Boston, Massachusetts) and Nitec Pharma SA (Basel, Switzerland). Over many years, he was the Chairman/Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd. Dr. Birner also represents the interests of TVM Capital with Ardana Bioscience plc (Edinburgh, Scotland).
return to top
Jeffrey D. Abbey, M.B.A., J.D.
Director
Jeffrey Abbey joined Argos Therapeutics in 2002. Before joining
Argos, Mr. Abbey was Vice President of Business Development and Finance
for Internet Appliance Network (IAN), a venture-backed information technology
company based in New York City. Prior to joining IAN, he was a partner
in Eilenberg and Krause, a boutique corporate law firm, where he acted
as business counsel for a number of life sciences and other emerging technology
companies. Mr. Abbey has extensive experience in structuring and negotiating
licenses, joint ventures and other technology transfer agreements, as well
as mergers, acquisitions and financing transactions. He holds an A.B. in
Mathematical Economics from Brown University and received an M.B.A. and
J.D. from the University of Virginia.
return to top
David W. Gryska
Director
Mr. Gryska joined our Board of Directors in January 2012. Since March 2005, he also serves as a board member at Seattle Genetics. From December 2006 to October 2010, Mr. Gryska was Senior Vice President and Chief Financial Officer of Celgene. Previously, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. From 1998 to 2004, Mr. Gryska was Senior Vice President and Chief Financial Officer at Scios, Inc., a biopharmaceutical company, where he led the transaction effort for the successful sale of the company to Johnson & Johnson for $2.5 billion in February 2003. From 1993 to 1998, he served as Vice President and Chief Financial Officer at Cardiac Pathways, a company later acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young (EY). During his eleven years at EY, he focused on technology industries, with an emphasis on biotechnology and healthcare companies. Mr. Gryska also serves on the Board of Directors of Hyperion Therapeutics. He holds a B.A. in accounting and finance from Loyola University and an M.B.A. from Golden Gate University.
return to top
Jean Lamarre
Director
Mr. Lamarre joined our Board of Directors in March 2013. As president of Lamarre Consultants, Mr. Lamarre brings to the Board more than 15 years of experience in strategic planning and corporate financing for life sciences and information technology companies. In addition to Argos Therapeutics, Mr. Lamarre sits on numerous boards, including Klox Technologies, Mispro Biotech Services inc. and CQVB. Previously, Mr. Lamarre was Vice President for Canam-Manac Group, one of the largest structural steel companies in North America. While in this role he supervised operations in Mexico, Venezuela, France and China. For 15 years, Mr. Lamarre worked for the Lavalin Group, one of the world´s largest engineering and construction firms. He went from managing international projects in Africa and Central America to CFO of the firm for seven years. He was also European Vice President, supervising operations in Belgium, France and England. Mr. Lamarre holds a Bachelor of Business Administration from HEC Montréal with a specialization in Applied Economics.
return to top
Philip R. Tracy, J.D.
Director
Philip R. Tracy was formerly the President and Chief Executive Officer
of Burroughs Wellcome Co., a major research-based pharmaceutical company
with $1.2 billion in sales and 5,000 employees. Mr. Tracy has served on
the boards of directors of the Pharmaceutical Research and Manufacturers
Association of America and the Nonprescription Drug Manufacturers Association.
Mr. Tracy is a venture partner with Intersouth Partners and currently serves
on the boards of directors of two Intersouth portfolio companies. He is
also Of Counsel with Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan,
L.L.P. He received his B.A. from University of Nebraska and his J.D. from
George Washington University.
return to top
Brian J. Underdown, B.Sc., Ph.D.
Director
Brian Underdown joined Lumira Capital (formerly, MDS Capital Corp) in 1997. His focus has been on
new company formation in both Canada and the United States. Prior to joining
MDSCC, Dr. Underdown held a number of senior management positions in the
biopharmaceutical industry and in universities. Dr. Underdown obtained
his Ph.D. in immunology from McGill University and undertook post-doctoral
studies at Washington University School of Medicine. During his academic
career, he focused on immune-mediated diseases as well as vaccine development.
During his tenure at MDSCC, Dr. Underdown has focused on new investment
opportunities and building value as a board member in a number of companies
including, ID Biomedical, Trillium Therapeutics and Cytochroma Inc. He
has been actively involved in policy development and grant administration
with a number of government and non-governmental organizations that support
research, especially as it applies to commercial development.
return to top
Sander van Deventer,
M.D., Ph.D.
Director
Sander van Deventer is Professor of Experimental Medicine at the Academic
Medical Center in Amsterdam and general partner of Forbion Capital Partners
(formerly, ABN AMRO Capital). Dr. van Deventer has held numerous academic
appointments and has been the principle clinical investigator for several
clinical trials. He has served on a number of regulatory and pharmaceutical
industry scientific advisory boards and has been an advisor to the Food
and Drug Administration. Dr. van Deventer received his M.D. and Ph.D. from
the University of Amsterdam.
return to top
|
|
|
|